Do analysts rate OSRH or STRR?

Star Equity has a consensus price target of $28.00, suggesting a potential upside of 146.05%. Given Star Equity's stronger consensus rating and higher probable upside, analysts clearly believe Star Equity is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Star Equity 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.20

Which has higher earnings & valuation, OSRH or STRR?

Star Equity has higher revenue and earnings than OSR. Star Equity is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 4.37 -$27.06M -$0.33 N/A Star Equity $172.16M 0.24 -$5.92M -$2.63 N/A

Is OSRH or STRR more profitable?

Star Equity has a net margin of -4.18% compared to OSR's net margin of -363.26%. Star Equity's return on equity of -4.04% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% Star Equity -4.18% -4.04% -2.40%

Do analysts recommend NTRB or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, NTRB or OSRH?

Nutriband has higher earnings, but lower revenue than OSR. Nutriband is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 17.76 -$8.23M -$2.58 N/A OSR $2.91M 4.37 -$27.06M -$0.33 N/A

Is NTRB or OSRH more profitable?

OSR has a net margin of -363.26% compared to Nutriband's net margin of -448.25%. OSR's return on equity of -7.24% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -448.25% -112.64% -97.86% OSR -363.26% -7.24% -5.41%

Do analysts prefer NEPH or OSRH?

Nephros currently has a consensus target price of $6.00, suggesting a potential upside of 69.01%. Given Nephros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nephros is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NEPH or OSRH?

Nephros has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.05 $1.19M $0.07 50.71 OSR $2.91M 4.37 -$27.06M -$0.33 N/A

Is NEPH or OSRH more profitable?

Nephros has a net margin of 4.06% compared to OSR's net margin of -363.26%. Nephros' return on equity of 7.66% beat OSR's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% OSR -363.26% -7.24% -5.41%

Do analysts rate OSRH or NSPR?

InspireMD has a consensus price target of $4.50, indicating a potential upside of 527.18%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InspireMD 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, OSRH or NSPR?

InspireMD has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OSR $2.91M 4.37 -$27.06M -$0.33 N/A InspireMD $10.85M 3.10 -$19.92M -$0.73 N/A

Is OSRH or NSPR more profitable?

OSR has a net margin of -363.26% compared to InspireMD's net margin of -413.96%. OSR's return on equity of -7.24% beat InspireMD's return on equity. Company Net Margins Return on Equity Return on Assets OSR -363.26% -7.24% -5.41% InspireMD -413.96% -69.42% -57.68%

Do analysts prefer TELA or OSRH?

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 193.14%. Given TELA Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe TELA Bio is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, TELA or OSRH?

OSR has lower revenue, but higher earnings than TELA Bio. OSR is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.42 -$38.83M -$0.79 N/A OSR $2.91M 4.37 -$27.06M -$0.33 N/A

Is TELA or OSRH more profitable?

TELA Bio has a net margin of -49.30% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -49.30% -1,320.81% -55.83% OSR -363.26% -7.24% -5.41%

OSR (OSRH) Competitors

$0.36 +0.01 (+1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 +0.00 (+0.25%)

As of 07:58 PM Eastern

Compare

OSRH vs. STRR, NTRB, NEPH, NSPR, and TELA

Should you buy OSR stock or one of its competitors? MarketBeat compares OSR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OSR include Star Equity (STRR), Nutriband (NTRB), Nephros (NEPH), InspireMD (NSPR), and TELA Bio (TELA). These companies are all part of the "medical equipment" industry.

How does OSR compare to Star Equity?

OSR (NASDAQ:OSRH) and Star Equity (NASDAQ:STRR) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

OSR has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Star Equity has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Star Equity has higher revenue and earnings than OSR. Star Equity is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A
Star Equity	$172.16M	0.24	-$5.92M	-$2.63	N/A

Star Equity has a consensus price target of $28.00, suggesting a potential upside of 146.05%. Given Star Equity's stronger consensus rating and higher probable upside, analysts clearly believe Star Equity is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

55.3% of OSR shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 36.8% of OSR shares are held by insiders. Comparatively, 31.6% of Star Equity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Star Equity has a net margin of -4.18% compared to OSR's net margin of -363.26%. Star Equity's return on equity of -4.04% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
Star Equity	-4.18%	-4.04%	-2.40%

In the previous week, OSR and OSR both had 1 articles in the media. Star Equity's average media sentiment score of 1.87 beat OSR's score of 0.94 indicating that Star Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
OSR	Positive
Star Equity	Very Positive

Summary

Star Equity beats OSR on 10 of the 16 factors compared between the two stocks.

How does OSR compare to Nutriband?

Nutriband (NASDAQ:NTRB) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

OSR has a net margin of -363.26% compared to Nutriband's net margin of -448.25%. OSR's return on equity of -7.24% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
OSR	-363.26%	-7.24%	-5.41%

19.7% of Nutriband shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 36.8% of OSR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nutriband and Nutriband both had 1 articles in the media. Nutriband's average media sentiment score of 1.89 beat OSR's score of 0.94 indicating that Nutriband is being referred to more favorably in the media.

Company	Overall Sentiment
Nutriband	Very Positive
OSR	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nutriband has higher earnings, but lower revenue than OSR. Nutriband is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	17.76	-$8.23M	-$2.58	N/A
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A

Nutriband has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market. Comparatively, OSR has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Summary

OSR beats Nutriband on 7 of the 13 factors compared between the two stocks.

How does OSR compare to Nephros?

Nephros (NASDAQ:NEPH) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Nephros has a net margin of 4.06% compared to OSR's net margin of -363.26%. Nephros' return on equity of 7.66% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
OSR	-363.26%	-7.24%	-5.41%

In the previous week, Nephros had 1 more articles in the media than OSR. MarketBeat recorded 2 mentions for Nephros and 1 mentions for OSR. Nephros' average media sentiment score of 0.94 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Nephros	Positive
OSR	Positive

Nephros has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, OSR has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

41.1% of Nephros shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 36.8% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nephros has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.05	$1.19M	$0.07	50.71
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A

Nephros currently has a consensus target price of $6.00, suggesting a potential upside of 69.01%. Given Nephros' stronger consensus rating and higher possible upside, equities research analysts clearly believe Nephros is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Nephros beats OSR on 12 of the 15 factors compared between the two stocks.

How does OSR compare to InspireMD?

OSR (NASDAQ:OSRH) and InspireMD (NYSE:NSPR) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

OSR has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

55.3% of OSR shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 36.8% of OSR shares are owned by company insiders. Comparatively, 34.1% of InspireMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

InspireMD has a consensus price target of $4.50, indicating a potential upside of 527.18%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, OSR had 1 more articles in the media than InspireMD. MarketBeat recorded 1 mentions for OSR and 0 mentions for InspireMD. OSR's average media sentiment score of 0.94 beat InspireMD's score of 0.00 indicating that OSR is being referred to more favorably in the media.

Company	Overall Sentiment
OSR	Positive
InspireMD	Neutral

OSR has a net margin of -363.26% compared to InspireMD's net margin of -413.96%. OSR's return on equity of -7.24% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-363.26%	-7.24%	-5.41%
InspireMD	-413.96%	-69.42%	-57.68%

InspireMD has higher revenue and earnings than OSR. OSR is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A
InspireMD	$10.85M	3.10	-$19.92M	-$0.73	N/A

Summary

OSR beats InspireMD on 9 of the 16 factors compared between the two stocks.

How does OSR compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and OSR (NASDAQ:OSRH) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

TELA Bio presently has a consensus price target of $2.20, suggesting a potential upside of 193.14%. Given TELA Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe TELA Bio is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TELA Bio and TELA Bio both had 1 articles in the media. TELA Bio's average media sentiment score of 1.89 beat OSR's score of 0.94 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Very Positive
OSR	Positive

OSR has lower revenue, but higher earnings than TELA Bio. OSR is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.42	-$38.83M	-$0.79	N/A
OSR	$2.91M	4.37	-$27.06M	-$0.33	N/A

TELA Bio has a net margin of -49.30% compared to OSR's net margin of -363.26%. OSR's return on equity of -7.24% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
OSR	-363.26%	-7.24%	-5.41%

TELA Bio has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, OSR has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 55.3% of OSR shares are owned by institutional investors. 5.1% of TELA Bio shares are owned by company insiders. Comparatively, 36.8% of OSR shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

TELA Bio beats OSR on 9 of the 15 factors compared between the two stocks.

Get OSR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSRH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OSRH vs. The Competition

Export

Metric	OSR	UNCLASSIFIED Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$12.50M	$152.57M	$4.39B	$12.45B
Dividend Yield	N/A	N/A	30.61%	8.43%
P/E Ratio	-1.10	35.62	19.41	21.94
Price / Sales	4.37	214.74	147.58	93.49
Price / Cash	N/A	2,548.24	165.47	59.36
Price / Book	0.07	37.42	12.86	6.33
Net Income	-$27.06M	-$17.90M	$118.20M	$331.02M
7 Day Performance	15.32%	-0.76%	-1.57%	-1.09%
1 Month Performance	-4.96%	-2.85%	-1.89%	-0.49%
1 Year Performance	-68.24%	-6.40%	9.05%	19.90%

OSR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OSRH OSR	0.8168 of 5 stars	$0.36 +1.7%	N/A	-69.8%	$12.50M	$2.91M	N/A	N/A
STRR Star Equity	4.2887 of 5 stars	$11.15 +1.5%	$28.00 +151.1%	+460.0%	$40.62M	$172.16M	N/A	1,200	Gap Down
NTRB Nutriband	0.9775 of 5 stars	$3.06 flat	N/A	-63.1%	$37.20M	$2.04M	N/A	10	Positive News
NEPH Nephros	2.1307 of 5 stars	$3.40 flat	$6.00 +76.5%	-0.3%	$36.91M	$18.79M	48.57	30	Gap Up High Trading Volume
NSPR InspireMD	3.3636 of 5 stars	$0.70 flat	$4.50 +543.8%	-69.5%	$32.74M	$10.85M	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OSRH) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OSR (OSRH) Competitors